AddLife AB (publ): history, ownership, mission, how it works & makes money

From a family-rooted enterprise founded in 1906 to a publicly traded powerhouse since Nasdaq Stockholm 2014, AddLife AB has grown into a European life-science platform with more than SEK 10 billion in net sales in 2024, roughly 2,300 employees across about 85 operating subsidiaries and an acquisition-led expansion-most recently the July 2024 purchase of BonsaiLab-that amplifies its Labtech and Medtech footprints; its capital structure of SEK 62,358,949 divided into 122,450,250 shares (4,572,796 Class A with ten votes each and 117,877,454 Class B with one vote each) produces a concentrated ownership where the ten largest shareholders control 51.3% of votes (51.7% of capital), Swedish entities hold 51.9% of capital and votes while foreign investors account for 36.4%, and the board targets a dividend policy of 30-50% of profit after tax with a proposed ordinary dividend of SEK 0.75 per share for 2024; operating through decentralized Labtech and Medtech divisions that sell equipment, consumables, reagents and services (technical support, training, consulting), AddLife pairs organic growth and targeted acquisitions (e.g., BonsaiLab, Pharmacold A/S in Dec 2025) to diversify revenue streams, bolster margins through efficiency measures, and serve hospitals, research institutions and the pharmaceutical/food industries across Europe.

AddLife AB (0REZ.L): Intro

• Founded: 1906
• Stock exchange listing: Nasdaq Stockholm, 2014
• Employees: ~2,300 (2024)
• Operating subsidiaries: ~85 (2024)
• Net sales: > SEK 10 billion (2024)
• Recent acquisition: BonsaiLab (July 2024)

History & Strategic Growth

• Early decades: establishment and regional distribution focus
• Late 20th - early 21st century: diversification into medtech and labtech offerings
• Post-2014: public listing used to fund bolt-on acquisitions and platform scaling
• 2024: strategic biotech strengthening via acquisition of BonsaiLab

Ownership & Corporate Structure

• Share structure: ordinary shares listed on Nasdaq Stockholm
• Governance: board and executive management with decentralized operating subsidiaries
• Capital use: acquisitions, working capital, operational investments

Mission, Vision & Values

How It Works - Business Model & Operations

• Labtech: laboratory equipment, reagents, consumables, service contracts for research labs, universities, biotech and pharma.
• Medtech: medical devices, diagnostics, consumables and aftermarket service primarily for healthcare providers.
• Shared capabilities: procurement, warehousing, technical service, regulatory support, and local sales networks.

How AddLife Makes Money - Revenue Streams & Profit Drivers

• Product sales: equipment and consumables (high recurring revenue from consumables and reagents).
• Service & maintenance contracts: installation, calibration, spare parts and field service (higher margin, recurring).
• Distribution agreements: exclusive or preferred supply contracts with global manufacturers.
• Acquisitions: bolt-on purchases that add revenue, specialized capabilities and local market share.
• Project sales: turnkey lab/clinical installations and major capital equipment deliveries.

Key Financial & Operational Indicators (Context)

• Net sales: > SEK 10 billion (2024) - reflects scale in European life sciences market.
• Employee base: ~2,300 across ~85 subsidiaries - indicates decentralized delivery model and local market penetration.
• Acquisition cadence: active - example: BonsaiLab (July 2024) to expand biotech services and product range.

AddLife AB (0REZ.L): History

• Founded and expanded via acquisitions focused on diagnostics, laboratory consumables, and medical devices.
• Transitioned from a regional distributor to a platform owner of specialist brands and service businesses.
• Strategy emphasizes add-on acquisitions, organic growth in service offerings and integration of logistics and sales.

• Dual-class share structure: Class A = 10 votes, Class B = 1 vote; equal dividend rights across classes.
• Concentrated control: ten largest shareholders control just over half of votes and capital.
• Significant domestic institutional presence (insurance companies, funds) holding a majority stake.
• Meaningful international investor base (36.4%), with notable holdings from USA, Norway, Luxembourg.

• Distribution and wholesale of diagnostic reagents, laboratory consumables and medical devices-margin on product sales and volume-driven revenue.
• Proprietary niche brands and specialist product portfolios-higher gross margins from owned brands and exclusive distribution agreements.
• Service offerings-maintenance, instrument service contracts, calibration and training that generate recurring revenue.
• Lab services and consumable replenishment-steady cash flow from contract customers and public healthcare institutions.
• M&A and integration-accretive acquisitions increase scale, cross-sell opportunities, and centralized purchasing savings.

• Share capital: SEK 62.36 million across 122.45 million shares.
• Dividend proposal: SEK 0.75 per share; Board targets 30-50% payout of profit after tax.
• Ownership concentration supports stable governance and the ability to pursue long-term acquisition strategy.

AddLife AB (0REZ.L): Ownership Structure

• Mission and Values: independence as a partner to healthcare providers; focus on innovation, efficiency and cost-effectiveness; strong compliance and sustainability commitments; culture of collaboration, expertise and continuous improvement; integrity and transparency in governance and operations.
• Operational focus: distribution & logistics, specialist sales teams, service contracts, and value-added consulting to hospitals, clinics and labs.
• Revenue model: product distribution margins, service agreements, maintenance contracts, and sales of proprietary and third‑party diagnostic and consumable products.

• Significant institutional ownership (Nordic mutual funds, pension funds).
• Management and board holdings aligned with long‑term value creation.
• Free float supporting liquidity on the exchange.

• Distribution margins on medical devices and consumables - primary revenue driver, benefiting from scale and logistics efficiency.
• Service and maintenance contracts - recurring revenue and higher-margin aftermarket sales.
• Value‑added services and consultancy - implementation, training and clinical support tied to device sales.
• Selective acquisitions - bolt‑on purchases to expand geographic reach, product portfolio and specialist capabilities, contributing to organic and inorganic growth.

AddLife AB (0REZ.L): Mission and Values

• Labtech: Supplies reagents, instruments, consumables and service solutions for biomedical research, diagnostics and laboratory analysis. Customers include universities, research institutes, clinical labs and biotech companies.
• Medtech: Offers medical devices and consumables for hospitals and healthcare providers across categories such as orthopedics, critical care, endoscopy, wound care and healthcare IT solutions.

• Organic growth: Revenue expansion through broadened product portfolios, deeper customer relationships and geographic expansion within Europe.
• Acquisition-driven growth: AddLife executes targeted acquisitions of specialist distributors and niche product companies to add complementary technologies, increase market share and enter new clinical segments.
• Decentralized structure: Subsidiaries operate with substantial autonomy-preserving local entrepreneurship, customer intimacy and technical competence-while being aligned to group-level strategy, finance and compliance.
• Customer-centric approach: Emphasis on technical support, training, service contracts and tailored solutions to meet specific workflows and regulatory needs across research and clinical customers.

• Product sales: High-volume sales of reagents, consumables and standardized medical products account for recurring revenue.
• Capital equipment: Sales and service agreements for laboratory instruments and clinical devices generate higher-margin transactions plus aftermarket service revenue.
• Service and maintenance: Calibration, maintenance, validation and consumable replenishment provide steady annuity-like income streams.
• Value-added solutions: Bundled offerings-training, implementation, IT integration and consulting-enhance margins and customer stickiness.
• M&A synergies: Post-acquisition integration and cross-selling raise revenue per customer and improve gross margin over time.

• Labtech: ~55% of group sales-dominant in diagnostics, research consumables and laboratory equipment.
• Medtech: ~45% of group sales-focused on hospital supplies, devices and clinical solutions.

• Recurring consumables and service contracts smooth revenue across quarters and support gross margin stability.
• Capital equipment cycles create periodic spikes in revenue but also long-term service revenue streams.
• Specialist niche products and distribution agreements provide pricing power in selected categories.
• Acquisition strategy targets profitable, cash-generative niche players to compound growth without diluting operational autonomy.

• Public company with majority ownership distributed among institutional investors and a group of long-term shareholders with industry experience.
• Governance model supports decentralized operating companies while centralizing capital allocation, M&A and compliance functions.

AddLife AB (0REZ.L): How It Works

• Primary segments: Labtech (laboratory instruments, consumables, reagents) and Medtech (medical devices and equipment).
• Customers: hospitals, clinical laboratories, research institutions, biotech and pharmaceutical companies, veterinary clinics and industrial labs.
• Go-to-market: direct sales, distributor partnerships, field service teams and e-commerce/order platforms for consumables.

• Product sales: core revenue from one-time equipment sales (capital goods) and repeatable sales of consumables and reagents that generate recurring revenue.
• Services: technical support, installation, calibration, maintenance contracts, training and consulting that increase lifetime value of customers and smooth revenue seasonality.
• Value-add distribution: sourcing, regulatory support, local aftermarket services and bundled solutions that justify premium pricing and improve customer retention.
• Acquisitions and portfolio expansion: strategic purchases (e.g., BonsaiLab in July 2024) to access new product categories, geographic markets and cross-sell opportunities.
• Operational levers: inventory and supply-chain optimisation, centralised shared services and margin-enhancing product mix shift (consumables + service share increases gross margins).

• Revenue mix: significant share from consumables & reagents plus a meaningful portion from equipment and services-this diversification reduces cyclicality.
• Growth levers: organic growth via new product introductions and geographic expansion, supplemented by bolt-on acquisitions to accelerate market entry.
• Cost focus: central procurement, logistics optimisation and shared-services scaling to improve operating margins.
• Acquisition impact: acquisitions such as BonsaiLab (July 2024) are expected to expand product portfolio and contribute incremental revenue and cross-sell synergies.

• Sales cycle: equipment sales driven by tendering and evaluation timelines; consumables deliver continuous follow-on purchases post-installation.
• Customer retention: uptime SLAs, training and consumable compatibility lock-in increase switching costs.
• Pricing strategy: premium pricing on value-added bundles (equipment + service + reagents) and tiered service contracts.
• Channel mix: direct sales in core markets complemented by distributor networks for market penetration and reach.

AddLife AB (0REZ.L): How It Makes Money

• Primary revenue streams: distribution of laboratory equipment and consumables, sale of diagnostics and medical devices, service and maintenance contracts, and proprietary or OEM product sales.
• Growth drivers: recurring consumables sales, long-term service agreements, and cross-selling after acquisitions.
• Strategic M&A: acquisitions strengthen product portfolios and open new geographic and end‑market channels (e.g., BonsaiLab and Pharmacold A/S in December 2025).

• How the economics work: high-margin recurring revenues from consumables and services; mid-margin equipment sales; acquisition-driven revenue and cost synergies that lift consolidated margins over time.
• Market position & outlook: strong European presence, continuing organic growth plus targeted acquisitions to expand offerings and geographical reach; positioned to benefit from rising healthcare and life-science spending and increased regulatory emphasis on quality and sustainability.